·   Log in

Archive for March 9th, 2010

Natco to relaunch generic nano drug Albupax to treat breast cancer after recall on toxicity fears

Tuesday, March 9, 2010 21:14

Natco Pharma is planning to relaunch the controversial nanotechnology-based breast cancer treatment Albupax in India following the Union health minister staying DCGI's order prohibiting the sale of the drug, reports said.

This was posted under category: Featured, Industry  |  Read Full Story  |  0 Comments
Tagged with: , ,

D-Pharm’s drug DP-b99 to control stroke damages could hit markets by 2013

Tuesday, March 9, 2010 19:53

DP-b99, an experimental medicine to control neurological damages caused by stroke, may reach the market earlier than expected --in 3 to 4 years' time, reports said quoting D-Pharm's senior officials.

This was posted under category: Clinical Trials  |  Read Full Story  |  0 Comments
Tagged with: , ,

Serum Institute lines up H1N1 vaccine Fluvac launch for May

Tuesday, March 9, 2010 14:13

The Serum Institute of India (SII), India's largest vaccine maker, has announced the commencement of the last crucial phases of human trials of its swine flu vaccine Fluvac.

This was posted under category: Biotech  |  Read Full Story  |  0 Comments

Tomato extract product Fruitflow can cut blood clot risks with no side-effect of aspirin, claims Provexis

Tuesday, March 9, 2010 14:05

Fruitflow, a tomato-extract product developed by Provexis, has been found effective to prevent blood clots that risk heart attacka nd strokes without the side-effects of the widely used blood thinner Aspirin.

This was posted under category: health  |  Read Full Story  |  0 Comments

Once-weekly immunoglobulin under skin injection Hizentra for primary immunodeficiency approved in US: CSL Behring

Tuesday, March 9, 2010 14:03

Hizentra, a 20 percent concentration of human immunoglobulin to be administered subcutaneously for treating patients diagnosed with primary immunodeficiency (PI), has been granted approval in US.

This was posted under category: Biotech  |  Read Full Story  |  0 Comments
Tagged with: ,